The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment
Authors:
- Sotirios PililisSPSotirios Pililis
- Stamatios LampsasStamatios Lampsas
- Aikaterini KountouriAKAikaterini Kountouri
- Loukia PlioutaLPLoukia Pliouta
- Emmanouil KorakasEmmanouil Korakas
- Sarantis LivadasSLSarantis Livadas
- John ThymisJohn Thymis
- Melpomeni PeppaMelpomeni Peppa
- Sophia KalantaridouSKSophia Kalantaridou
- Evangelos OikonomouEvangelos Oikonomou
- Ignatios IkonomidisIgnatios Ikonomidis
- Vaia LambadiariVLVaia Lambadiari
Open Access
Abstract
Polycystic Ovarian Syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, with significant variations in presentation characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Beyond reproductive health, it may also pose crucial long-term cardiometabolic risks, especially for women with specific types of PCOS, contributing to early subclinical cardiovascular atherosclerotic alterations such as endothelial dysfunction, increased arterial stiffness, and coronary artery calcium levels, respectively. Moreover, the precise relationship between clinical cardiovascular disease (CVD) and PCOS remains debated, with studies demonstrating an elevated risk while others report no significant association. This review investigates the pathophysiology of PCOS, focusing on insulin resistance and its link to subclinical and clinical cardiovascular disease. Diagnostic challenges and novel management strategies, including lifestyle interventions, medications like metformin and glucagon-like peptide-1 receptor agonists (GLP-1RAs), hormonal contraceptives, and bariatric surgery, are further discussed. Recognizing the cardiometabolic risks associated with PCOS, a comprehensive approach and early intervention should address both the reproductive and cardiometabolic dimensions of the syndrome.Keywords
This publication has 161 references indexed in Scilit:
- Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysisIrish Journal of Medical Science (1971 -), 2023
- Ketogenic Diet as Medical Prescription in Women with Polycystic Ovary Syndrome (PCOS)Current Nutrition Reports, 2023
- Effects of Bariatric Surgery on People with Obesity and Polycystic Ovary Syndrome: a Large Single Center Study from IndiaObesity Surgery, 2022
- The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysisJournal of Endocrinological Investigation, 2021
- Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndromeEndocrine, 2021
- Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an updateArchives of Gynecology and Obstetrics, 2021
- Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysisEndocrine, 2017
- The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysisObesity Surgery, 2015
- Adipose Tissue Dysfunction in Polycystic Ovary SyndromeCurrent Diabetes Reports, 2011
- The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)Diabetologia, 2006